Jobless Claims Remain Low Signaling Continued Labor Market Strength Could the Fed Raise Rates in July Yardeni Warns of Bond Vigilante Pressure on Incoming Chair Warsh UOB Faces High Court Criticism Over Inconsistent Legal Stance on Late Mortgage Charges Diversified Energy Acquires Permian Basin Natural Gas Player Maverick Resources China Calls for APEC Economic Cooperation as Commerce Minister Skips Meeting Over Urgent Official Business National Retail Federation Projects 44 Growth in US Retail Sales for 2026 ARMK Q1 2026 Earnings EPS Slightly Misses Estimates Amid Mixed Market Reaction XBIO Q2 2025 Earnings Loss Narrows Despite No Revenue as Biotech Advances Pipeline Novagold Resources NG Q1 2026 Earnings Narrower Loss Drives 74 Stock Gain General Motors Q1 2026 Earnings Strong EPS Beat Drives Stock Higher NeoVolta NEOV Q1 2026 Earnings EPS Beats Estimates Despite Revenue Absence Stock Drops 2364 SAIC Q1 2026 Earnings Strong EPS Beat Driven by Operational Efficiency Range Capital Acquisition Corp II Warrants RNGTW Flat at 032 as Warrants Trade Near Support Unicycive Therapeutics UNCY Surges 59 as Shares Test Key Resistance CVD Equipment Corporation CVV Surges Over 4 Key Levels to Watch Regencell Bioscience RGC Edges Higher Approaches Key Resistance Level InvenTrust Properties IVT Edges Higher Testing Resistance Levels as REIT Sector Shows Stability Lixte Biotechnology LIXT Holds Near Support After Slight Decline Better Home Finance Holding Warrants BETRW Slide Sharply as Support Level Under Threat Codere Online CDRO Edges Higher Testing Key Resistance Zone Ensysce Biosciences ENSC Declines Further Tests Key Support Near 029 PMGC Holdings Inc ELAB Pulls Back 23 as Sellers Test Support Near 162 Cerus Corporation CERS Consolidates Near 273 as Support and Resistance Levels Hold Kevin Warsh Vows ReformOriented Approach as New Federal Reserve Chair RYTM Q1 2026 Earnings NarrowerthanExpected Loss Drives Positive Stock Reaction Optical Cable Corporation OCC Surges Over 10 as Fiber Optic Demand Drives Momentum JANX Q1 2026 Earnings NarrowerthanExpected Loss Buoys Biotech Sentiment PRE Q4 2025 Earnings EPS Falls Sharply Short of Expectations Amid Transition Visa Q1 2026 Earnings EPS Beats Estimates by 482 as Payments Volume Remains Resilient YSS Q1 2026 Earnings EPS Misses Estimates by Wide Margin as PreRevenue Stage Continues LTRN Q1 2026 Earnings NarrowerThanExpected Loss Highlights Operational Discipline Amid No Revenue CLDX Q1 2026 Earnings Slight EPS Miss as DevelopmentStage Biotech Continues NoRevenue Phase PATK Q1 2026 Earnings EPS Surpasses Estimates Amid Strong Operational Execution